The Minimum Effective Dose (ED90) of Liposomal Bupivacaine for Preserving Motor Function (NCT06587386) | Clinical Trial Compass
CompletedPhase 4
The Minimum Effective Dose (ED90) of Liposomal Bupivacaine for Preserving Motor Function
China55 participantsStarted 2025-05-20
Plain-language summary
Explore the minimum effective dose of liposomal bupivacaine for preserving motor function
Who can participate
Age range41 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Age 41-65 years ASA physical condition 1-3 BMI 18-30 kg/m2 undergoing arthroscopic shoulder surgery
Exclusion Criteria:
Inability to consent to the study pregnancy allergy to local anesthetics preexisting neuropathy cervical pathologies (i.e., herniated disc, myelopathy) chronic pain syndromes (defined as reflex sympathetic dystrophy or complex regional pain syndrome) severe respiratory conditions psychiatric or cognitive disorders that prohibit patients from adhering to the study protocol history of drug or alcohol abuse chronic opioid use (longer than 3 months or daily morphine equivalents more than 5mg/day for 1 month) contraindication for general anesthesia and/or interscalene nerve block and planned open shoulder arthrotomies Muscle related diseases
What they're measuring
1
ED90 of motor function was preserved 72 hours after brachial plexus block